Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Farnesyl Protein Transferase Inhibitor · 2 trials · 6 indications
| Name | Type | Description |
|---|---|---|
| Farnesyl Protein Transferase Inhibitor | DRUG | - |
Inclusion Criteria: * Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. * Life expectancy of 12 weeks or greater. * ECOG Performance Status less than or equal to 2. * Meets protocol requirements for spe...
Top 20 of 63 competitors
Farnesyl Protein Transferase Inhibitor is an investigational small molecule being studied for the treatment of leukemia and neoplasms. It has been evaluated in patients with leukemia, myelodysplastic syndromes, chronic myeloid leukemia in blast crisis, lymphocytic leukemia, and advanced solid tumors. The drug is still in clinical development and is not approved.
Farnesyl Protein Transferase Inhibitor is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company has sponsored clinical trials of this investigational oncology drug.
Farnesyl Protein Transferase Inhibitor is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in leukemia and related conditions and another in advanced solid tumors. The drug remains investigational and has not been approved.
Farnesyl Protein Transferase Inhibitor has been studied in two completed Phase 1 trials. NCT00034684 enrolled 132 patients with leukemia, myelodysplastic syndromes, chronic myeloid leukemia in blast crisis, and lymphocytic leukemia. NCT00040547 enrolled 29 patients with advanced solid tumors and combined the drug with docetaxel.
Farnesyl Protein Transferase Inhibitor works by inhibiting farnesyl protein transferase, an enzyme involved in the farnesylation of proteins. This process is important for the function of certain proteins that can drive cancer cell growth. By blocking this enzyme, the drug aims to disrupt cancer cell signaling.